SAN FRANCISCO, June 26 /PRNewswire/ -- Synarc Inc., the world’s leading provider of medical imaging analysis, biochemical marker, and subject recruitment services to the pharmaceutical and biotechnology industries, today announced the appointment of Jeffrey J. Bairstow to executive vice president and chief financial officer. Bairstow will be responsible for directing the company’s financial, legal and administrative operations.
Prior to joining Synarc, Bairstow served as EVP and CFO at Dendrite, a pharmaceutical sales services company in Bedminster, New Jersey. Bairstow was responsible for the company’s financial operations, including planning, investor relations and internal audit.
“We are delighted that Jeff has joined us,” said Gary Velasquez, chief executive officer of Synarc. “The combination of his financial, operational and relevant industry experience will be a tremendous asset as we continue to grow and execute our development plans.
“In addition, Jeff brings several years of managing global financial operations as well as being a senior officer in several publicly-traded organizations. We look forward to Jeff’s contributions to Synarc’s financial, operational and strategic development.”
Bairstow received his B.A. from Vanderbilt University and his Master’s in Business Administration from Vanderbilt’s Owen School of Business. Synarc was formed in 1998 and since then has contributed to the approval of more leading compounds, across a broad spectrum of therapeutic areas, than any other central imaging provider.
About Synarc
Synarc’s medical image-analysis, subject-recruitment, and biochemical- marker services enable life-science industry clients to execute clinical trials accurately while decreasing the time, uncertainty, and cost of product development. Synarc has partnered with industry leaders to bring numerous leading compounds to market across a broad spectrum of therapeutic areas. Our services integrate critical aspects of clinical-trial design and execution, from protocol design and subject recruitment to regulatory liaison on behalf of our clients. Our expert radiologists and scientists are innovators in all aspects of medical imaging and biochemical markers in drug development, and have pioneered many methods used in today’s clinical trials. Synarc has seventeen offices around the world and currently manages over 200 clinical trials.
Synarc Inc.
CONTACT: Natalie Cummins of Synarc Inc., +1-201-213-1361,natalie.cummins@synarc.com
